DrugPatentWatch Database Preview
Details for New Drug Application (NDA): 075136
NDA 075136 describes VERAPAMIL HYDROCHLORIDE, which is a drug marketed by Mylan, Abraxis Pharm, Bedford, Hospira, Intl Medication, Luitpold, Marsam Pharms Llc, Smith And Nephew, Solopak, Exela Pharma Scs Llc, Apotex Corp, Cadila Pharms Ltd, Glenmark Generics, Ivax Sub Teva Pharms, Par Pharm, Pliva, Sun Pharm Inds Inc, Actavis Elizabeth, Heritage Pharms Inc, Mutual Pharm, Sun Pharm Industries, Warner Chilcott, Watson Labs, and Yaopharma Co Ltd, and is included in fifty-three NDAs. It is available from thirty-seven suppliers. Additional details are available on the VERAPAMIL HYDROCHLORIDE profile page.
The generic ingredient in VERAPAMIL HYDROCHLORIDE is verapamil hydrochloride. There are seventeen drug master file entries for this compound. Thirty-nine suppliers are listed for this compound. Additional details are available on the verapamil hydrochloride profile page.
The generic ingredient in VERAPAMIL HYDROCHLORIDE is verapamil hydrochloride. There are seventeen drug master file entries for this compound. Thirty-nine suppliers are listed for this compound. Additional details are available on the verapamil hydrochloride profile page.
Summary for 075136
| Tradename: | VERAPAMIL HYDROCHLORIDE |
| Applicant: | Hospira |
| Ingredient: | verapamil hydrochloride |
| Patents: | 0 |
| Therapeutic Class: | Cardiovascular Agents |
| Formulation / Manufacturing: | see details |
Suppliers and Packaging for NDA: 075136
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| VERAPAMIL HYDROCHLORIDE | verapamil hydrochloride | SOLUTION;INTRAVENOUS | 075136 | ANDA | Hospira, Inc. | 0409-9633 | N | 0409-9633-05 |
| VERAPAMIL HYDROCHLORIDE | verapamil hydrochloride | SOLUTION;INTRAVENOUS | 075136 | ANDA | General Injectables & Vaccines, Inc | 52584-633 | N | 52584-633-05 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAVENOUS | Strength | 5MG/2ML (2.5MG/ML) | ||||
| Approval Date: | Oct 20, 1998 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
